Medimaps Group SA, a leading provider of AI-assisted bone microarchitecture imaging solutions, and Radiobotics ApS, a provider of AI-assisted musculoskeletal radiology solutions, announced they have entered into a strategic merger agreement. Completion of the transaction is subject to Danish Foreign Direct Investment (FDI) approval and other customary closing conditions.
The merger will unite the two companies specializing in AI-powered medical imaging analysis to accelerate the adoption of AI-assisted musculoskeletal imaging, combining complementary technologies, strong clinical validation and global commercial capabilities around a common vision.
The new organization will offer a comprehensive suite of solutions covering X-ray and densitometry (DXA) modalities, ranging from automated fracture detection and opportunistic bone fragility assessment to fracture risk prediction. Medimaps Group‘s bone microarchitecture solutions – TBS Osteo™ and TBS Reveal™ – along with RBfracture™, Radiobotics’ flagship solution for traumatic injury detection, seamlessly integrate into existing radiology workflows thanks to PACS-compatible capabilities.
Also Read: Trimedx Expands AI‑Native Trimedx‑AIQ with Supply Chain Automation
Its mission will be to address the silent crisis in bone health by bridging the gap between reactive diagnosis and preventative care. This partnership will create the first AI-assisted imaging product ecosystem capable of addressing musculoskeletal health throughout the patient journey, where every X-ray will become a tool for both detecting and predicting long-term risk. To achieve this goal at scale, the organization will leverage its combined clinical expertise, operational capabilities, and established distribution networks to expand access to its product portfolio in 90 markets worldwide, including the United States, serving hospitals, clinics, and imaging centers.
“This merger represents a pivotal step in Medimaps Group’s long-term strategy to strengthen our leadership position in bone health assessment,” said Prof. Didier Hans, co-founder and CEO of Medimaps Group. “Our ambition is to offer radiologists a single, reliable platform that combines fracture detection and fracture risk prediction across the continuum of care, enabling clinicians to make better decisions, improve patient outcomes, and help healthcare systems deliver more effective, clinically evidence-based care.”
A combined leadership team from both companies will guide the new organization, ensuring strategic and operational continuity while preserving the musculoskeletal expertise of both. By retaining key leaders from both sides, the group will be ideally positioned to foster a high-growth, collaborative environment that respects the heritage of both companies.
“Radiobotics has always been guided by scientific rigor and tangible clinical benefits,” says Peter Ulvskjold, CEO of Radiobotics and a member of the Medimaps Group Executive Committee. “Joining Medimaps Group will accelerate access to our technology. This is an important step in our vision to ensure that patients receive immediate, targeted, and high-quality musculoskeletal imaging care 24/7, regardless of time, infrastructure, or staffing constraints.”
Fractures remain one of the most frequent and operationally demanding challenges for hospitals and emergency departments. High volumes of trauma, the need for rapid decision-making, and the risk of missed or delayed diagnoses place constant pressure on clinicians and care pathways. Improving the speed and consistency of fracture assessment is therefore essential for patient outcomes and hospital efficiency.
Osteoporosis and associated fragility fractures alone represent a major clinical and economic burden on health systems, with annual costs currently estimated at $22 billion and likely to exceed $95 billion by 2040.
Early identification of bone fragility and accurate fracture risk assessment are essential for prompt intervention and preventing fractures before they occur. By leveraging AI-assisted imaging solutions such as RBfracture™, TBS Reveal™, and TBS Osteo™, radiologists can more effectively identify at-risk patients and support proactive clinical management.
SOURCE: Businesswire
